Format

Send to

Choose Destination
Expert Opin Investig Drugs. 2017 Apr;26(4):415-426. doi: 10.1080/13543784.2017.1302425. Epub 2017 Mar 9.

Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials.

Author information

1
a Department of Oncology , Montefiore Medical Center/Albert Einstein College of Medicine , Bronx , NY , USA.

Abstract

It remains challenging to treat squamous cell lung cancer (SCC) with limited therapeutic options. However, recent breakthroughs in targeted therapies and immunotherapies have shed some light on the management of this deadly disease. Areas covered: The article first reviews the current treatment options for advanced SCC, especially recent FDA approved molecular agents (afatinib, ramucirumab and necitumumab) and immunotherapies (nivolumab, pembrolizumab and atezolimumab). We then provide an overview on investigational therapies with data ranging from preclinical to phase II studies, focusing on new cytotoxic agents, emerging molecularly targeted agents (including a PARP inhibitor for Homologous Recombinant Deficiency positive SCC) and novel immunotherapeutic strategies. Expert opinion summary: Identification of potential therapeutic targets, development of novel clinical trials and the rapid approvals of immune checkpoint inhibitors have shifted the management paradigm for squamous cell lung cancer. On the other hand, continued efforts are needed to identify the predictive biomarkers and to investigate novel mechanistically-driven mono- and combination therapies. We need to learn more about the biology behind immune checkpoint blockade and tumor genomics in SCC for better patient selection and future trial design.

KEYWORDS:

Squamous cell lung cancer; immunotherapy; novel therapy; targeted therapy

PMID:
28277882
DOI:
10.1080/13543784.2017.1302425
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center